SCHEMBL6799540

SCHEMBL6799540

COc1ccc2c(c1)C(=O)C1(Cc3ccccc3C1)C2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIB P23284 1/20 0.58
METAP1 P53582 2/20 0.49
MAOB P27338 2/20 0.47
ALDH1A1 P00352 5/20 0.47
GAA P10253 3/20 0.47
HPGD P15428 3/20 0.47
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
ALOX12 P18054 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ACHE P22303 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800097 0.92 METAP1 (0.54) PPIBMETAP1MAOBALDH1A1GAA
SCHEMBL6801984 0.88 SIGMAR1 (0.54) PPIBMETAP1MAOBALDH1A1GAA
SCHEMBL6796531 0.88 PPIB (0.55) PPIBMETAP1MAOBALDH1A1GAA
SCHEMBL6795670 0.85 CES2 (0.45) PPIBMETAP1MAOBALDH1A1GAA
SCHEMBL6794626 0.83 METAP1 (0.51) PPIBMETAP1MAOBALDH1A1SMN1; SMN2
SCHEMBL11805867 0.82 METAP1 (0.47) PPIBMETAP1MAOBALDH1A1GAA
SCHEMBL19737862 0.81 METAP1 (0.51) PPIBMETAP1MAOBALDH1A1GAA
SCHEMBL23986655 0.81 METAP1 (0.46) PPIBMETAP1ALDH1A1GAASMN1; SMN2
SCHEMBL29993125 0.81 METAP1 (0.46) PPIBMETAP1ALDH1A1GAASMN1; SMN2
SCHEMBL6799152 0.81 METAP1 (0.49) PPIBMETAP1MAOBALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082642-A1 Novel estrogen receptor ligands and method III MERCK & CO., INC. 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082642-A1 Novel estrogen receptor ligands and method III ESRRA, ESRRB, FSHR PPIB 1888/4885METAP1 4145/4885MAOB 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.